Share on:
Copy to clipboard 
Orthofix posted 1Q17 revenue of US $102.7MM, +4.1% from 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Trauma | $23.9 | $24.7 | -$0.8 | -3.1% |
| Spine | $19.3 | $18.8 | $0.4 | 2.3% |
| Orthobiologics | $15.0 | $14.1 | $0.9 | 6.3% |
| Other (Biostim) | $44.5 | $41.0 | $3.5 | 8.5% |
| Total | $102.7 | $98.7 | $4.1 | 4.1% |
1Q17 performance highlights:
- Other/Biostim increase attributed to next-gen products and a growing base of prescribing physicians, in light of supportive NASS coverage recommendation
- Trauma sales driven by TrueLok Hex system in the U.S., offset by divestiture of non-core business in the U.K. (had contributed ~$0.5MM net sales to each quarter in 2016)
- Spine has returned to growth sooner than expected, with growth driven by U.S. sales due to improved distributor engagement, new distribution partners and product launches, offset by reduced collections vs. 1Q16 in ex-U.S. cash-based businesses
- Launched Cetra Anterior Cervical Plate; planning >12 line extensions in spine for 2017
- Biologics revenue also returned to growth ahead of expectations, supported by strong Trinity Elite volume growth from distributors added in 2016, partially offset by low-single-digit reduction in ASP for Trinity as a result of increased competition
- After quarter’s close, launched JuniOrtho brand to house products and services that treat pediatric orthopaedic and congenital deformities (presently, >1/3 of extremity fixation business is pediatric)
- Additional 2Q17 launches include a differentiated disposable delivery system for Trinity, while remaining 2017 launches will focus on U.S. foot/ankle and targeted ex-U.S. trauma markets
- In 2016, added 66 distributors overall; of that, half were for Biologics and a “significant number” for spine
- Guiding to 2017 revenue in the range of $411MM to $415MM
Source: Orthofix International N.V.
Orthofix posted 1Q17 revenue of US $102.7MM, +4.1% from 1Q16.
Q17
Q16
$ Change
% Change
Trauma
$23.9
$24.7
-$0.8
-3.1%
Spine
$19.3
$18.8 ...
Orthofix posted 1Q17 revenue of US $102.7MM, +4.1% from 1Q16.
| 1Q17 | 1Q16 | $ Change | % Change | |
| Trauma | $23.9 | $24.7 | -$0.8 | -3.1% |
| Spine | $19.3 | $18.8 | $0.4 | 2.3% |
| Orthobiologics | $15.0 | $14.1 | $0.9 | 6.3% |
| Other (Biostim) | $44.5 | $41.0 | $3.5 | 8.5% |
| Total | $102.7 | $98.7 | $4.1 | 4.1% |
1Q17 performance highlights:
- Other/Biostim increase attributed to next-gen products and a growing base of prescribing physicians, in light of supportive NASS coverage recommendation
- Trauma sales driven by TrueLok Hex system in the U.S., offset by divestiture of non-core business in the U.K. (had contributed ~$0.5MM net sales to each quarter in 2016)
- Spine has returned to growth sooner than expected, with growth driven by U.S. sales due to improved distributor engagement, new distribution partners and product launches, offset by reduced collections vs. 1Q16 in ex-U.S. cash-based businesses
- Launched Cetra Anterior Cervical Plate; planning >12 line extensions in spine for 2017
- Biologics revenue also returned to growth ahead of expectations, supported by strong Trinity Elite volume growth from distributors added in 2016, partially offset by low-single-digit reduction in ASP for Trinity as a result of increased competition
- After quarter’s close, launched JuniOrtho brand to house products and services that treat pediatric orthopaedic and congenital deformities (presently, >1/3 of extremity fixation business is pediatric)
- Additional 2Q17 launches include a differentiated disposable delivery system for Trinity, while remaining 2017 launches will focus on U.S. foot/ankle and targeted ex-U.S. trauma markets
- In 2016, added 66 distributors overall; of that, half were for Biologics and a “significant number” for spine
- Guiding to 2017 revenue in the range of $411MM to $415MM
Source: Orthofix International N.V.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
